Inspire Medical reports Q2 revenue decline, raises guidance, launches $30M growth plan

Filed August 3, 2026 · Period ending August 3, 2026 · ~1 min read

Key Changes

• high

  Q2 2026 revenue fell 7.6% YoY to $200.6M due to U.S. coding and reimbursement challenges; company raised full-year revenue guidance to $835M-$875M and adjusted EPS to $1.05-$1.45, signaling confidence despite headwinds.

  Item 2.02 verify on EDGAR →
• high

  Announced Project Horizon restructuring to unlock $30M in annualized growth investment capacity; expects $20M-$25M in pre-tax charges ($4M-$5M employee-related, $16M-$20M non-cash), with most actions complete by Q3 2026.

  Exhibit 99.1 view on EDGAR →
• medium

  Gross margin expanded 150 bps to 85.5% driven by favorable product mix toward higher-margin Inspire V system; Q2 operating cash flow improved to $23.2M from $2.7M prior year.

  Exhibit 99.1 view on EDGAR →